医学
脂肪变性
肝硬化
肝细胞癌
非酒精性脂肪肝
放射科
慢性肝病
肝病
胃肠病学
病理
脂肪肝
疾病
内科学
作者
Jitka Starekova,Diego Hernando,Perry J. Pickhardt,Scott B. Reeder
出处
期刊:Radiology
[Radiological Society of North America]
日期:2021-09-21
卷期号:301 (2): 250-262
被引量:114
标识
DOI:10.1148/radiol.2021204288
摘要
Hepatic steatosis is defined as pathologically elevated liver fat content and has many underlying causes. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with an increasing prevalence among adults and children. Abnormal liver fat accumulation has serious consequences, including cirrhosis, liver failure, and hepatocellular carcinoma. In addition, hepatic steatosis is increasingly recognized as an independent risk factor for the metabolic syndrome, type 2 diabetes, and, most important, cardiovascular mortality. During the past 2 decades, noninvasive imaging-based methods for the evaluation of hepatic steatosis have been developed and disseminated. Chemical shift–encoded MRI is now established as the most accurate and precise method for liver fat quantification. CT is important for the detection and quantification of incidental steatosis and may play an increasingly prominent role in risk stratification, particularly with the emergence of CT-based screening and artificial intelligence. Quantitative imaging methods are increasingly used for diagnostic work-up and management of steatosis, including treatment monitoring. The purpose of this state-of-the-art review is to provide an overview of recent progress and current state of the art for liver fat quantification using CT and MRI, as well as important practical considerations related to clinical implementation. © RSNA, 2021 Online supplemental material is available for this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI